Drug Delivery Partnering Terms and Agreements -





 

Publication Date: January 2014 | Version: 5 | Pages: 2,427

The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

                                

This report contains over 2,500 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. 

 The drug delivery technology includes the following sub-technology areas:

 

Drug Delivery 

  

  • Bioavailability
  • Implanatable
  • Oral delivery
    • Rapid release
    • Delayed release
  • Parenteral
    • Infusion
    • Injectable
     
  • Pro-drug
  • Targeted
  • Tropical
  • Transdermal
    • Buccal
    • Inhaled
    • Nasal
    • Ocular
    • Rectal
    • Sublingual
    • Urogenital
     

 

The initial chapters of this report provide an orientation of drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

                            

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2007.

In addition, a comprehensive appendix is provided organized by drug delivery partnering company A-Z, deal type definitions and drug delivery partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.

 

Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to drug delivery trends and structure of deals entered into by leading companies worldwide.

                                

Drug Delivery Partnering Terms and Agreements includes:

                                                        

  • Trends in drug delivery dealmaking in the biopharma industry since 2007
  • Analysis of drug delivery deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life drug delivery deals
  • Access to over 2,500 drug delivery contract documents
  • The leading drug delivery deals by value since 2007
  • Most active drug delivery dealmakers since 2007
  • The leading drug delivery partnering resources

 

 

In Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


 

  

  

Executive Summary 

 

Chapter 1 – Introduction 

 

Chapter 2 – Trends in drug delivery dealmaking 

 

2.1. Introduction

2.2. Drug delivery partnering over the years

2.3. Big pharma drug delivery dealmaking activity

2.4. Big biotech drug delivery dealmaking activity

2.5. Most active drug delivery dealmakers

2.6 Drug delivery partnering by deal type

2.7. Drug delivery partnering by disease type

2.8. Partnering by drug delivery technology type

2.9. Average deal terms for drug delivery partnering

2.9.1 Drug delivery headline values

2.9.2 Drug delivery upfront payments

2.9.3 Drug delivery milestone payments

2.9.4 Drug delivery royalty rates

2.10. The anatomy of drug delivery partnering

2.11. Drug delivery or specialty pharma?

2.11.1. Is specialty pharma the only way for drug delivery?

2.11.2. Best practice for optimizing drug delivery program development

2.11.3. The anatomy of a drug delivery deal

2.11.3.a. Case study 1: Uluru – Oradisc

2.11.3.b. Case study 2: Bayer – MDRNA

2.11.3.c. Case study 3: Endo Pharmaceuticals – BioDelivery Sciences

 

Chapter 3 – Leading drug delivery deals 

 

3.1. Introduction

3.2. Top drug delivery deals by value

 

Chapter 4 – Bigpharma drug delivery deals 

 

4.1. Introduction 

 

4.2. How to use big pharma drug delivery partnering deals 

 

4.3. Big pharma drug delivery partnering company profiles 

Abbott

Actavis

Actavis (Acquired by Watson)

Allergan

Allergan

Amgen

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Endo Pharmaceuticals

Forest Laboratories

Fresenius

Galderma

Gilead Sciences

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Menarini

Merck & Co

Merck KGaA

Mylan

Novartis

Novo Nordisk

Otsuka

Pfizer

Purdue

Ranbaxy Laboratories

Roche

Sanofi

Servier

Shionogi

Shire

Stada

Takeda

Teva

UCB

Valeant

Warner Chilcott

 

Chapter 5 – Big biotech drug delivery deals 

 

5.1. Introduction 

5.2. How to use big biotech partnering deals 

5.3. Big biotech drug delivery partnering company profiles 

3SBio

Acorda Therapeutics

Actelion

Alexion Pharmaceuticals

Alkermes

AMAG Pharmaceuticals

Amgen

Array Biopharma

Biocon

Biogen Idec

BioMarin Pharmaceuticals

Cangene

Celgene

Cubist

Dendreon

Elan

Emergent BioSolutions

Galapagos

Gilead Sciences

Grifols

Ipsen

Isis Pharmaceuticals

LFB Group

Morphosys

Nektar Therapeutics

Novo Nordisk

NPS Pharmaceuticals

PDL BioPharma

Questcor Pharmaceuticals

Regeneron Pharmaceuticals

SciClone Pharmaceuticals

Seattle Genetics

Spectrum Pharmaceuticals

Swedish Orphan Biovitrum

The Medicines Company

United Therapeutics

Vertex Pharmaceuticals

ViroPharma

 

Chapter 6 – Drug delivery partnering contracts directory 

 

6.1. Introduction 

6.2. Company A-Z 

3M

3M Drug Delivery Systems

3SBio

Abbott Laboratories

Abraxis BioScience

Accentia Biopharmaceuticals

Accredo Health Group

Acelrx Pharmaceuticals

Acorda Therapeutics

Actavis (Acquired by Watson)

Actient Pharmaceuticals

Acura Pharmaceuticals

Acusphere

Adams Respiratory Therapeutics

Adeona Pharmaceuticals

Adolor

Advanced Life Sciences

Alchemia

Alexion Pharmaceuticals

Alexza Pharmaceuticals

Alfacell

Alimera Sciences

Alkermes

Allergan

Allos Therapeutics

Alnylam Pharmaceuticals

Alpharma

Alpharma Ireland

Altus Pharmaceuticals

Amag Pharmaceuticals

Amarillo Biosciences

Amarin

Amicus Therapeutics

Ampio Pharmaceuticals

Amylin Pharmaceuticals

Anacor Pharmaceuticals

ANDRx

Anesiva

Anesta

Angiodynamics

Angiotech Pharmaceuticals

AnorMed

AP Pharma

Apricus Biosciences

Aradigm

Aristos Pharmaceuticals

Arius Pharmaceuticals

ArQule

Arrow International

ARYx Therapeutics

Astellas Pharma

AstraZeneca

Atley Pharmaceuticals

Audeo Oncology

Auxilium Pharmaceuticals

AVANT Immunotherapeutics

AVI Pharma

Azur Pharma

Banner Pharmacaps

Barrier Therapeutics

Bausch & Lomb

Baxter International

Baxter Oncology GmbH

Bayer

Bayer Healthcare

Ben Venue Laboratories

Bentley Pharmaceuticals

Biken

Bio-Path

BioAlliance Pharma

BioArray Solutions

BioCryst Pharmaceuticals

BioDelivery Sciences

Biofield

Biogen Idec

BiolineRX

Biomedical Advanced Research and Development Authority

BioMerieux

BioMimetic Therapeutics

Biopharmex

Biopure

BioSante Pharmaceuticals

BioSpecifics Technologies

Biovail

Biovail Laboratories

BioVest

BioZone Laboratories

Brand Builders International

Brand Builders Rx

Breath

Bristol-Myers Squibb

Brookwood Pharmaceuticals

Brotech

Caleco Pharma

Caleco Pharma Europe

Callisto Pharmaceuticals

Cambridge Laboratories

Caraco Pharmaceuticals

Cardinal Health

Cardium Therapeutics

Cary Pharmaceuticals

Catalent Pharma Solutions

Cato BioVentures

Celladon

Celsion

Cephalon

Cepheid

Cerus

Chrysalis Technologies

Clarus Therapeutics

Coating Place

CollaGenex

Columbia Laboratories

CombinatoRx

Contract Pharmaceuticals

Control Delivery Systems

CorMedix

Cornerstone Biopharma

Cornerstone Therapeutics

Cortex Pharmaceuticals

Cosmo Technologies

CP Pharmaceuticals

CPEX Pharmaceuticals

Crawford Healthcare

Critical Therapeutics

Cubist Pharmaceuticals

Cumberland Pharmaceuticals

Cutanea Life Sciences

CV Therapeutics

Cyclacel Pharmaceuticals

CyDex

Cypress Bioscience

Daewoong Pharmaceutical

Daiichi Sankyo

Dainippon Sumitomo Pharma

Dalian Wande Electronics

Debiopharm

Dechra Veterinary Products

Defense Threat Reduction Agency

Dehaier Medical Systems

Department of Defense

Department of Health and Human Services

Department of Homeland Security

DepoMed

Desitin

Dey Pharma

Diomed

Discovery Laboratories

DNA Biomedical Solutions

DoctorDirectory

DOR BioPharma

Dov Pharmaceutical

Dow Pharmaceutical Sciences

DPT Laboratories

Draxis Pharma

Drugs for Neglected Diseases Initiative

Duramed

Durect

DUSA Pharmaceuticals

Dyax

Echo Therapeutics

ECR Pharmaceuticals

EDK Therapeutics

EKR Therapeutics

Elan

Eli Lilly

Elite Pharmaceuticals

Emergent BioSolutions

Emisphere

Endo Pharmaceuticals

Entera Bio

Enzon Pharmaceuticals

Epic Pharmaceuticals

EpiCept

Esprit Pharma

Evonik Industries

Facet Biotechnology

FasTrack Pharmaceuticals

Ferndale Pharmaceuticals

Finorga

Fleet Laboratories

Flynn Pharma

Forbes Medi-Tech

Fovea Pharmaceuticals

Genaera

Genentech

Generex Biotechnology

Genta

GenVec

Genzyme

Ghent University

GlaxoSmithKline

Global Health Ventures

Globe Laboratories

GlobeImmune

GPC Biotech

Graceway Pharmaceuticals

Green Vision

Grifols

Grunenthal

Hadasit Medical Research Services and Development

Halozyme Therapeutics

Hangzhou Zhencheng Pharmaceuticals

Hebei Huaxing Pharmaceuticals

Hebei Kiwa Huaxing Bio-Pharmaceuticals

Helix BioMedix

Helix BioPharma

HemispheRx Biopharma

Heraeus

Hermes BioScience

Horizon Pharma AG

Horizon Pharma Inc

Hospira

Hunan Jiuwang Pharmaceuticals

Hydron Technologies

Idea

IDIS Pharma

Ikaria

ImaRX

ImClone Systems

Immunomedics

Impax Laboratories

Imprimis Pharmaceuticals

Inalco Biochemicals

Inalco Group

Incyte

Indevus Pharmaceuticals

Inex Pharmaceuticals

Inovio Pharmaceuticals

InSite Vision

Insmed Inc

Inspire Pharmaceuticals

Institut Biochimique

Intas Biopharmaceuticals

IntelGenx

Intendis

Intercell

Intergen

InterMune

Intrexon

Iomai

Ipsen

ISTA Pharmaceuticals

Ivax

Jagotec

Javelin Pharmaceuticals

Jazz Pharmaceuticals

JDS Pharmaceutical

JHP Pharmaceuticals

Jiangsu Yabang Pharmaceuticals

Johns Hopkins University

Johnson & Johnson

JPI Commercial

Kensey Nash

Keryx Biopharmaceuticals

Kinetic Concepts

King Pharmaceuticals

Kiwa Bio-Tech Products

Klarogen Biotherapeutics

Krele Pharmaceuticals

Kunwha Pharmaceuticals

KV Pharmaceutical

Kwang Dong Pharmaceuticals

Kyowa Hakko Kogyo

Kythera Biopharmaceuticals

Lees Pharmaceutical

Lenetix

Ligand Pharmaceuticals

Lipocine

Lonza

Los Angeles Biomedical Research Institute

Lung Rx

Lupin Pharmaceuticals

Macrochem

Mallinckrodt

MAP Pharmaceuticals

Marina Biotech

Massachusetts Institute of Technology

McCoy Enterprises

McKesson

McNeil PPC

MD Anderson Cancer Center

MDRNA

Meda

Medgenics

Medical Futures

MediciNova

Medicis Pharma

Medpace

Medtronic

Meiji Seika

Memorial Sloan Kettering Cancer Center

Memory Pharmaceuticals

Menarini

Merck and Co

Merial

Merrimack Pharmaceuticals

Mglas

Microbix Biosystems

MiddleBrook Pharmaceutical

Mikah Pharma

Millennium

Mirna Therapeutics

Mist Acquisition

Monsanto

Mova Pharmaceuticals

Mundipharma

Mutual Pharmaceutical

Mylan Laboratories

Nastech Pharmaceutical

National Institute of Allergy and Infectious Diseases

National Institute of Infectious Diseases

ND Partners

Nektar Therapeutics

Neos Therapeutics

NeurogesX

Neurokine Pharmaceuticals

Neuromed

NeuroMed Devices

Neuronex

NexMed

Nitec Pharma

NitroMed

Nof

Norgine

Northern Lipids

Nova Biomedical

NovaBay Pharmaceuticals

NovaCardia

Novacea

NovaDel Pharma

Novartis

Novartis Consumer Health

Novasep

Noven Pharmaceuticals

Novo Nordisk

Novozymes Biopharma

NuGlow Cosmaceuticals

NuPathe

Nycomed

Obagi Medical Products

Ocimum Biosolutions

Oculus Innovative Sciences

Oklahoma Medical Research Foundation

Omthera Pharmaceuticals

OncoSec Medical

Ono Pharmaceutical

Ophthalmic Research Associates

Oradisc

Oramed Pharmaceuticals

Ore Pharmaceuticals

Orexigen Therapeutics

Orion

Oso Bio Pharmaceuticals

Pacific Beach Biosciences

Pacira Pharmaceuticals

Paladin Labs

Panion

Par Pharmaceutical

Paramount Biosciences

Patheon

PDL BioPharma

Pfizer

Pharmaceutical Innovations

Pharmacopeia

PharmaEngine

Philip Morris Products

Pipex Pharmaceuticals

Planned Systems International (PSI)

Polymun Scientific Immunbiologische

Poniard Pharmaceuticals

Porex

Pozen

Prasco Laboratories

Precision Pharma Services

Prestige Brands

Procter & Gamble

Procter & Gamble Pharmaceuticals

Professional Compounding Centers of America

Progenics Pharmaceuticals

ProNAi Therapeutics

Proteolix

PSivida

Purdue Pharma

QLT

QLT USA

QuatRx Pharmaceuticals

Questcor Pharmaceuticals

Quintiles

Radius Health

Rechon Life Sciences

Reckitt Benckiser

RedHill Biopharma

Repligen

RevImmune

Rib-X Pharmaceuticals

Rigel Pharmaceuticals

Roche

Rodan and Fields

Rohto Pharmaceuticals

Royalty Securitization Trust

S2 Therapeutics

Sagent Pharmaceuticals

Salix Pharmaceuticals

Sam Amer

Sangamo BioSciences

Sankyo Pharmaceutical

Sanofi-Aventis

Santarus

Santen Pharmaceutical

Savient Pharmaceuticals

Schering-Plough

Scolr Pharma

Seattle Genetics

Select Vaccines

Senetek

Sepracor

Sequenom

Serenity Pharmaceuticals

Shaanxi Aoxing Pharmaceutical

Shaanxi Jiali Pharmaceuticals

Shandong Yaoshan Pharmaceuticals

Shijiazhuang-Unigene Pharmaceuticals

Shijiazhuang Pharmaceutical

Shionogi

Shire Pharmaceuticals

SIGA Technologies

Sigma-Aldrich

Sigma-Tau

SignPath Pharmaceuticals

SK Biopharmaceuticals

SkyePharma

SLA Pharma

Solvay

Southern Research Institute

Sovereign Pharmaceuticals

Spectrum Pharmaceuticals

Spring Creek Capital

SRI International

Strakan

Strativa Pharmaceuticals

Sun Pharmaceutical

Sunovion Pharmaceuticals

Supernus Pharmaceuticals

SurModics

SurModics Pharmaceuticals

Symphony Allegro

Takeda Pharmaceutical

Tanabe Seiyaku

Targanta Therapeutics

Tarsa Therapeutics

Teikoku Pharma USA

Teikoku Seiyaku

Tekmira Pharmaceuticals

Tercica

Teva Pharmaceuticals

The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center

The Medicines Company

The Regents of the University of California

Therabel

TPG Capital

Transcept Pharmaceuticals

Transdel Pharmaceuticals

Transition Therapeutics

Tranzyme Pharma

Triax Aesthetics

Tris Pharma

TTY Biopharm

UCB

Uluru

Unigene Laboratories

United Therapeutics

Valeant Pharmaceuticals

Vanda Pharmaceuticals

Ventrus Biosciences

VeroScience

VetCure

VIA Pharmaceuticals

Victory Pharma

Viropharma

Vivus

WA 32609

Wanbang Anesiva (Jiangsu) Biotech

Wanbang Biopharmaceuticals

Warner Chilcott

Washington Research Foundation

Watson Laboratories

Watson Pharmaceuticals

Wockhardt

Wyeth

Xianyang Materia Medica

Xi’an Zaolutang Kushidai Pharmaceuticals

XTL Biopharmaceuticals

Yakult Honsha

Yamasa

Zogenix

ZymoGenetics

 

6.3. By deal type 

 

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Litigation

Loan

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

 

6.4. By stage of development 

 

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

Regulatory

 

6.5. By therapy area 

 

Anaesthetics

Cardiovascular

Central Nervous System

Dental

Dermatology

Gastrointestinal

Genetic disorders

Genitourinary

Gynaecology

Hematology

Hospital care

Immunology

Infectives

Metabolic

Musculoskeletal

Obstetrics

Oncology

Ophthalmics

Pediatrics

Psychiatry

Public Health

Respiratory

Sexual Health

 

Chapter 7 – Drug delivery dealmaking by technology type 

 

7.1. Introduction 

 

7.2. Deals by drug delivery type 

 

Drug delivery

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

  

See accompanying volume for: 

  

Appendices 

  

Introduction 

 

Appendix 1 – Directory of drug delivery deals by company A-Z 2007-2013

 

Appendix 2 – Directory of drug delivery deals by stage of development 2007-2013

 

Appendix 3 – Directory of drug delivery deals by deal type 2007-2013    

 

Appendix 4 – Directory of drug delivery deals by therapy area 2007-2013

 

Appendix 5 – Drug delivery partnering resource center  

Online drug delivery partnering 

Drug delivery partnering events

Further reading on drug delivery dealmaking

 

 Table of figures 

 

Figure 1: Drug delivery partnering since 2007

Figure 2: Big pharma – top 50 – drug delivery deals 2007 to 2013

Figure 3: Big pharma drug delivery deal frequency – 2007 to 2013

Figure 4: Big biotech – top 50 – drug delivery deals 2007 to 2013

Figure 5: Big biotech drug delivery deal frequency – 2007 to 2013

Figure 6: Active drug delivery dealmaking activity– 2007 to 2013

Figure 7: Drug delivery partnering by deal type since 2007

Figure 8: Drug delivery partnering by disease type since 2007

Figure 9: Drug delivery partnering by technology type since 2007

Figure 10: Drug delivery deals with a headline value

Figure 11: Drug delivery deal headline value distribution, US$million – discovery stage

Figure 12: Drug delivery deal headline value distribution, US$million – preclinical stage

Figure 13: Drug delivery deal headline value distribution, US$million – phase I stage

Figure 14: Drug delivery deal headline value distribution, US$million – phase II stage

Figure 15: Drug delivery deal headline value distribution, US$million – phase III stage

Figure 16: Drug delivery deal headline value distribution, US$million – regulatory stage

Figure 17: Drug delivery deal headline value distribution, US$million – marketed stage

Figure 18: Summary median headline value by stage of development, 2007-2013

Figure 19: Drug delivery deals with upfront payment values

Figure 20: Drug delivery deal upfront payment distribution, US$million – discovery stage

Figure 21: Drug delivery deal upfront payment distribution, US$million – preclinical stage

Figure 22: Drug delivery deal upfront payment distribution, US$million – phase I stage

Figure 23: Drug delivery deal upfront payment distribution, US$million – phase II stage

Figure 24: Drug delivery deal upfront payment distribution, US$million – phase III stage

Figure 25: Drug delivery deal upfront payment distribution, US$million – regulatory stage

Figure 26: Drug delivery deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2007-2013

Figure 28: Drug delivery deals with milestone payments

Figure 29: Drug delivery deal milestone distribution, US$million – discovery stage

Figure 30: Drug delivery deal milestone distribution, US$million – preclinical stage

Figure 31: Drug delivery deal milestone distribution, US$million – phase I stage

Figure 32: Drug delivery deal milestone distribution, US$million – phase II stage

Figure 33: Drug delivery deal milestone distribution, US$million – phase III stage

Figure 34: Drug delivery deal milestone distribution, US$million – regulatory stage

Figure 35: Drug delivery deal milestone distribution, US$million – marketed stage

Figure 36: Drug delivery deals with royalty rates, %

Figure 37: Drug delivery deal royalty rate distribution, US$million – discovery stage

Figure 38: Drug delivery deal royalty rate distribution, US$million – preclinical stage

Figure 39: Drug delivery deal royalty rate distribution, US$million – phase I stage

Figure 40: Drug delivery deal royalty rate distribution, US$million – phase II stage

Figure 41: Drug delivery deal royalty rate distribution, US$million – phase III stage

Figure 42: Drug delivery deal royalty rate distribution, US$million – regulatory stage

Figure 43: Drug delivery deal royalty rate distribution, US$million – marketed stage

Figure 44: Summary median royalty rate by stage of development, 2007-2013

Figure 45: Components of the typical drug delivery deal structure

Figure 46: Best practice for drug delivery program development

Figure 47: Top drug delivery deals by value since 2007